LMTK2 and prostate cancer: We further confirmed this finding using subcellular fractionation, to enrich a nuclear fraction, which too showed presence of LMTK2 in nuclear and non-nuclear compartment of prostate cancer cells, irrespective of its androgen exposure (Fig. 2D).